RecruitingNot applicableNCT05641142
Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
Studying Hereditary hemorrhagic telangiectasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Clermont-Ferrand
- Principal Investigator
- Vincent GROBOSTUniversity Hospital, Clermont-Ferrand
- Intervention
- monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease(other)
- Enrollment
- 100 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (18)
- CHU d'Angers, Angers, France
- CHU de Bordeaux, Bordeaux, France
- Hôpital Ambroise Paré, Boulogne-Billancourt, France
- CHU de Caen Normandie, Caen, France
- CHU clermont-ferrand, Clermont-Ferrand, France
- CHU de Dijon, Dijon, France
- CHRU de Lille, Lille, France
- Hospices Civiles de Lyon, Lyon, France
- Assistance Publique - Hôpitaux de Marseille, Marseille, France
- CHU de Montpellier, Montpellier, France
- CHU de Nancy, Nancy, France
- CHU de Nantes, Nantes, France
- CHU de Nice, Nice, France
- AP-HP - Hôpital Ténon, Paris, France
- CHU de Poitiers, Poitiers, France
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05641142 on ClinicalTrials.govOther trials for Hereditary hemorrhagic telangiectasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07255846A Trial of TER-1754 in Patients With Hereditary Hemorrhagic TelangiectasiaTerremoto Biosciences Inc.
- ENROLLING BY INVITATIONNCT07445347Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia NetworkPoitiers University Hospital
- RECRUITINGPHASE1, PHASE2NCT06659640A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Alnylam Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07018401Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment StudyMassachusetts General Hospital
- ENROLLING BY INVITATIONNCT06261333Quality of Life in Patients With Hemorrhagic TelangiectasiaUniversity Hospital, Essen
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03850964Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)Cure HHT
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05406362Assess Safety and Efficacy of VAD044 in HHT PatientsVaderis Therapeutics AG
- RECRUITINGPHASE2NCT04976036Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) PatientsDr. Romain Lazor